Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CXCL12 is a pleiotropic, primarily homeostatic CXC chemokine that binds CXCR4 and ACKR3 to regulate leukocyte trafficking, stem/progenitor cell retention in bone marrow, angiogenesis, and embryogenesis; it exists as multiple human splice variants and is tightly regulated by expression, glycosaminoglycan binding, oligomerization, and post-translational modifications. In pathology, particularly cancer, the CXCL12/CXCR4/CXCR7 axis activates diverse signaling cascades (MAPK, PI3K, calcium/β-arrestin) to promote proliferation, survival, metastasis, angiogenesis, and therapy resistance, making the axis a therapeutic target for antagonists and ligand-directed inhibitors.
CXCR4 antagonism blocks CXCL12-induced Gαi signaling, calcium mobilization, MAPK/PI3K activation, chemotaxis, and survival signals in tumor and immune cells. Ligand sequestration or neutralization (small molecules binding CXCL12 to prevent receptor engagement). Modulation of ACKR3 (CXCR7) scavenging/biased signaling to alter CXCL12 availability and downstream signaling profiles.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on C-X-C motif chemokine ligand 12 (CXCL12) (CXCL12).